A New Era For Pricing and Access
Our Access & Pricing solution powered by OKRA.ai, allows pharma professionals to understand the value of a drug, 2 to 8 years prior to launch. It can be a pipeline asset, a competitor asset, a custom drug profile or a licensing opportunity.
The Access & Pricing system harnesses regulatory and pricing submissions to evaluate drugs based on preliminary Target Product Profiles, making predictions on future benefit assessment and pricing outcomes. The system discerns the value proposition of early-stage molecules and understands the value and drivers of negotiated prices for molecules earlier in the pipeline, reducing the burden and cost for pharma companies. Our AI brain helps you to understand the landscape, identify the analog and get you prepared for a new drug launch.